An Extension of the TG1101‐RMS201 Trial



Status:Enrolling by invitation
Conditions:Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 55
Updated:1/12/2019
Start Date:June 1, 2017
End Date:September 30, 2019

Use our guide to learn which trials are right for you!

An Open Label Extension of the TG1101‐RMS201 Trial, for Subjects Currently Enrolled in TG1101‐RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis

This study evaluates the long term use of a single agent ublituximab, a novel monoclonal
antibody, in patients with relapsing forms of multiple sclerosis


Inclusion Criteria:

- Subjects currently enrolled in TG1101-RMS201 trial

- Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and
Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled
assessments up to the final 48-week visit

Exclusion Criteria:

- Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101-
RMS201 study during the 48-week evaluation period

- Subjects who have started any other immunomodulating or disease modifying therapy
after completion of the TG1101-RMS201 trial

- Pregnant or nursing mothers
We found this trial at
6
sites
Columbus, Ohio 43210
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Knoxville, Tennessee 37922
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lexington, Kentucky 40513
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Round Rock, Texas 78681
?
mi
from
Round Rock, TX
Click here to add this to my saved trials
1830 Alametos
San Antonio, Texas 78258
?
mi
from
San Antonio, TX
Click here to add this to my saved trials